
GH Research PLC (GHRS)
Last updated: 2026-10-24 16:14:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Summary
GH Research PLC (GHRS) operates in the -- sector and is listed on NASDAQ. The stock is currently priced at $18.06, with a market capitalization of $1.27B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $12.04 to $31.44. This page covers its latest market performance, valuation, price trends and company information.
Key Market Data
$1.27B | |
$18.46 | |
$31.44 | |
$5.05 | |
$18.50 | |
659.22K | |
295.71K | |
-- | |
$31.44 | |
$12.04 | |
-- | |
-- |
GH Research PLC (GHRS) Latest Closing Stock Price
GH Research PLC (GHRS) last closed at $18.50 as of 2026-10-23 23:31:00, unchanged from the previous close of $18.50.
During the latest regular trading session, GHRS traded between $5.05 and $31.44, with a volume of 659.22K shares. The closing price was near the middle and near the lower end of its 52-week range.
GH Research PLC (GHRS) 7-Day Stock Price Change
Over the past seven days, GH Research PLC (GHRS) moved from $18.81 to $18.06, representing a decline of 4.00% ($0.75).
The stock traded between $17.54 and $19.81 during the period. The latest price is near the lower end of the 7-day range, indicating moderate downward.
The average daily volume was 351.77 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
GHRS 52-Week Price Position
Position in Range: 31.0%
GHRS is currently trading at $18.06, placing it 31.0% of the way from its 52-week low of $12.04 to its 52-week high of $31.44. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
What is GH Research PLC (GHRS)?
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.
GH Research PLC Information
| Employees | 73 |
| Exchange | NASDAQ |
| Company Website |
How to Buy GH Research PLC (GHRS) Stock on MEXC
Eligible investors can buy real shares of GH Research PLC (GHRS) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Frequently Asked Questions (FAQ)
1.What is GH Research PLC (GHRS) stock price today?
2.Is GHRS stock going up or down today?
3.What is GHRS pre-market price?
4.What is GHRS after-hours price?
5.Is GHRS stock trading now?
6.Where does GHRS sit relative to its 52-week high and low?
7.What sector is GH Research PLC in?
8.What is GH Research PLC's market capitalization and where is it listed?
9.How is GHRS valued in terms of P/E ratio and EPS?
10.Does GH Research PLC pay a dividend?
Explore More US Stocks
Search Stocks
GHRS Stock Calculator
Estimate the value between GHRS shares and USD.
GHRS Shares to USD
1.00 GHRS shares = 18.057 USD
Calculations are estimates based on the latest available price and are for reference only.


